SLC5A2 and type 2 diabetes mellitus: As a sodium-glucose co-transporter type 2 (SGLT2) inhibitor, dapagliflozin primarily acts on renal receptors to increase glucose excretion, a mechanism widely utilized in the management of type 2 diabetes [23].